Pfizer Inc. PFE announced today the company's pneumococcal
conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate
vaccine [13-valent, adsorbed]), received European approval for an
expanded indication to include adults aged 18 to 49 years for active
immunization for the prevention of invasive disease caused by
vaccine-type Streptococcus pneumoniae (S. pneumoniae).1
Previously approved in the European Union (EU) for use in infants, young
children and adolescents aged 6 weeks to 17 years, as well as adults 50
years of age and older, Prevenar 13 is now the only pneumococcal vaccine
in the EU that offers protection against invasive disease from infancy
through adulthood.1 The European Commission is the first to
approve Prevenar 13 to offer protection against invasive disease at all
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in